Mylan launches biosimilar Herceptin in India
This article was originally published in Scrip
Executive Summary
Mylan, Biocon's co-marketing partner for biosimilar Herceptin (trastuzumab) in India, says it has launched the product in the country. Biocon, which confirmed pricing details last month, said previously it would also make its product available from this week.